{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:17:23Z","timestamp":1784211443029,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-03015-9","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T20:21:41Z","timestamp":1721161301000},"page":"1249-1255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risks of major bleeding and venous thromboembolism in patients undergoing total hip or total knee arthroplasty using therapeutic dosages of DOACs"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5296-1151","authenticated-orcid":false,"given":"Mark J. R.","family":"Smeets","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5637-3581","authenticated-orcid":false,"given":"Eskild Bendix","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1214-5923","authenticated-orcid":false,"given":"Banne","family":"Nemeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1423-5348","authenticated-orcid":false,"given":"Menno V.","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4707-2303","authenticated-orcid":false,"given":"Suzanne C.","family":"Cannegieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3288-9401","authenticated-orcid":false,"given":"Alma Becic","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"3015_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/17453674.2019.1611215","volume":"90","author":"AB Pedersen","year":"2019","unstructured":"Pedersen AB, Andersen IT, Overgaard S et al (2019) Optimal duration of anticoagulant thromboprophylaxis in total hip arthroplasty: new evidence in 55,540 patients with osteoarthritis from the Nordic Arthroplasty Register Association (NARA) group. Acta Orthop 90:298\u2013305. https:\/\/doi.org\/10.1080\/17453674.2019.1611215","journal-title":"Acta Orthop"},{"key":"3015_CR2","doi-asserted-by":"publisher","first-page":"CD004179","DOI":"10.1002\/14651858.CD004179.pub2","volume":"3","author":"R Forster","year":"2016","unstructured":"Forster R, Stewart M (2016) Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair. Cochrane Database Syst Rev 3:CD004179. https:\/\/doi.org\/10.1002\/14651858.CD004179.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"3015_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1302\/0301-620X.96B4.33209","volume":"96\u2013B","author":"AB Pedersen","year":"2014","unstructured":"Pedersen AB, Mehnert F, Sorensen HT et al (2014) The risk of venous thromboembolism, myocardial infarction, stroke, major bleeding and death in patients undergoing total hip and knee replacement. Bone Jt J 96\u2013B:479\u2013485. https:\/\/doi.org\/10.1302\/0301-620X.96B4.33209","journal-title":"Bone Jt J"},{"key":"3015_CR4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1302\/0301-620X.88B3.17207","volume":"88\u2013B","author":"BT Bj\u00f8rnar\u030a","year":"2006","unstructured":"Bj\u00f8rnar\u030a BT, Gudmundsen TE, Dahl OE (2006) Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br 88\u2013B:386\u2013391. https:\/\/doi.org\/10.1302\/0301-620X.88B3.17207","journal-title":"J Bone Joint Surg Br"},{"key":"3015_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jama.2022.13416","volume":"328","author":"CRISTAL Study Group","year":"2022","unstructured":"CRISTAL Study Group (2022) Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL Randomized Trial. JAMA 328:719\u2013727. https:\/\/doi.org\/10.1001\/jama.2022.13416","journal-title":"JAMA"},{"key":"3015_CR6","doi-asserted-by":"publisher","first-page":"21233","DOI":"10.1038\/s41598-020-77127-6","volume":"10","author":"PB Petersen","year":"2020","unstructured":"Petersen PB, Kehlet H, J\u00f8rgensen CC, Lundbeck Foundation Centre for Fast-track Hip and Knee Replacement Collaborative Group (2020) Improvement in fast-track hip and knee arthroplasty: a prospective multicentre study of 36,935 procedures from 2010 to 2017. Sci Rep 10:21233. https:\/\/doi.org\/10.1038\/s41598-020-77127-6","journal-title":"Sci Rep"},{"key":"3015_CR7","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1055\/s-0038-1675641","volume":"118","author":"P Petersen","year":"2018","unstructured":"Petersen P, Kehlet H, J\u00f8rgensen C, on behalf of the Lundbeck Foundation Centre for Fast-track Hip and Knee Replacement Collaborative Group (2018) Safety of In-Hospital only Thromboprophylaxis after fast-track total hip and knee arthroplasty: a prospective Follow-Up study in 17,582 procedures. Thromb Haemost 118:2152\u20132161. https:\/\/doi.org\/10.1055\/s-0038-1675641","journal-title":"Thromb Haemost"},{"key":"3015_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/jth.15132","volume":"19","author":"B Nemeth","year":"2021","unstructured":"Nemeth B, Nelissen R, Arya R, Cannegieter S (2021) Preventing VTE following total hip and knee arthroplasty: is prediction the future? J Thromb Haemost JTH 19:41\u201345. https:\/\/doi.org\/10.1111\/jth.15132","journal-title":"J Thromb Haemost JTH"},{"key":"3015_CR9","doi-asserted-by":"publisher","first-page":"101782","DOI":"10.1016\/j.jcot.2022.101782","volume":"26","author":"H Khatkar","year":"2022","unstructured":"Khatkar H, Elahi Z, See A et al (2022) Preventing venous thromboembolism after elective total hip arthroplasty surgery \u2013 are the current guidelines appropriate? Venous thromboembolism prophylaxis in elective total hip arthroplasty surgery. J Clin Orthop Trauma 26:101782. https:\/\/doi.org\/10.1016\/j.jcot.2022.101782","journal-title":"J Clin Orthop Trauma"},{"key":"3015_CR10","doi-asserted-by":"publisher","first-page":"720","DOI":"10.7326\/0003-4819-156-10-201205150-00423","volume":"156","author":"DM Sobieraj","year":"2012","unstructured":"Sobieraj DM, Lee S, Coleman CI et al (2012) Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: a systematic review. Ann Intern Med 156:720\u2013727. https:\/\/doi.org\/10.7326\/0003-4819-156-10-201205150-00423","journal-title":"Ann Intern Med"},{"key":"3015_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.thromres.2006.12.025","volume":"120","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI, Borris LC, Dahl OE et al (2007) Dose-escalation study of rivaroxaban (BAY 59-7939) \u2013 an oral, direct factor xa inhibitor \u2013 for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 120:685\u2013693. https:\/\/doi.org\/10.1016\/j.thromres.2006.12.025","journal-title":"Thromb Res"},{"key":"3015_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1538-7836.2005.01657.x","volume":"4","author":"BI Eriksson","year":"2006","unstructured":"Eriksson BI, Borris L, Dahl OE et al (2006) Oral, direct factor xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost JTH 4:121\u2013128. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01657.x","journal-title":"J Thromb Haemost JTH"},{"key":"3015_CR13","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","volume":"5","author":"MR Lassen","year":"2007","unstructured":"Lassen MR, Davidson BL, Gallus A et al (2007) The efficacy and safety of apixaban, an oral, direct factor xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost JTH 5:2368\u20132375. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02764.x","journal-title":"J Thromb Haemost JTH"},{"key":"3015_CR14","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/j.1538-7836.2004.00890.x","volume":"2","author":"BI Eriksson","year":"2004","unstructured":"Eriksson BI, Dahl OE, Ahnfelt L et al (2004) Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost JTH 2:1573\u20131580. https:\/\/doi.org\/10.1111\/j.1538-7836.2004.00890.x","journal-title":"J Thromb Haemost JTH"},{"key":"3015_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","volume":"3","author":"BI Eriksson","year":"2005","unstructured":"Eriksson BI, Dahl OE, B\u00fcller HR et al (2005) A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost JTH 3:103\u2013111. https:\/\/doi.org\/10.1111\/j.1538-7836.2004.01100.x","journal-title":"J Thromb Haemost JTH"},{"key":"3015_CR16","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.106.642074","volume":"114","author":"BI Eriksson","year":"2006","unstructured":"Eriksson BI, Borris LC, Dahl OE et al (2006) A once-daily, oral, direct factor xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 114:2374\u20132381. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.642074","journal-title":"Circulation"},{"key":"3015_CR17","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1111\/j.1538-7836.2010.04021.x","volume":"8","author":"T Fuji","year":"2010","unstructured":"Fuji T, Fujita S, Tachibana S, Kawai Y (2010) A dose-ranging study evaluating the oral factor xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost JTH 8:2458\u20132468. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.04021.x","journal-title":"J Thromb Haemost JTH"},{"key":"3015_CR18","doi-asserted-by":"publisher","unstructured":"Sweetland S, Green J, Liu B et al (2009) Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ 339. https:\/\/doi.org\/10.1136\/bmj.b4583","DOI":"10.1136\/bmj.b4583"},{"key":"3015_CR19","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1001\/jamasurg.2019.3742","volume":"154","author":"A Caron","year":"2019","unstructured":"Caron A, Depas N, Chazard E et al (2019) Risk of Pulmonary Embolism more than 6 weeks after surgery among Cancer-Free Middle-aged patients. JAMA Surg 154:1126\u20131132. https:\/\/doi.org\/10.1001\/jamasurg.2019.3742","journal-title":"JAMA Surg"},{"key":"3015_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2147\/CLEP.S99498","volume":"8","author":"PH Gundtoft","year":"2016","unstructured":"Gundtoft PH, Varnum C, Pedersen AB, Overgaard S (2016) The Danish hip Arthroplasty Register. Clin Epidemiol 8:509\u2013514. https:\/\/doi.org\/10.2147\/CLEP.S99498","journal-title":"Clin Epidemiol"},{"key":"3015_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SAJ, Sandegaard JL et al (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449\u2013490. https:\/\/doi.org\/10.2147\/CLEP.S91125","journal-title":"Clin Epidemiol"},{"key":"3015_CR22","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/ije\/dyw213","volume":"46","author":"A Potteg\u00e5rd","year":"2017","unstructured":"Potteg\u00e5rd A, Schmidt SAJ, Wallach-Kildemoes H et al (2017) Data Resource Profile: the Danish national prescription Registry. Int J Epidemiol 46:798\u2013798f. https:\/\/doi.org\/10.1093\/ije\/dyw213","journal-title":"Int J Epidemiol"},{"key":"3015_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/CLEP.S30050","volume":"4","author":"AB Pedersen","year":"2012","unstructured":"Pedersen AB, Mehnert F, Odgaard A, Schr\u00f8der HM (2012) Existing data sources for clinical epidemiology: the Danish knee Arthroplasty Register. Clin Epidemiol 4:125\u2013135. https:\/\/doi.org\/10.2147\/CLEP.S30050","journal-title":"Clin Epidemiol"},{"key":"3015_CR24","doi-asserted-by":"publisher","first-page":"e012832","DOI":"10.1136\/bmjopen-2016-012832","volume":"6","author":"J Sundb\u00f8ll","year":"2016","unstructured":"Sundb\u00f8ll J, Adelborg K, Munch T et al (2016) Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open 6:e012832. https:\/\/doi.org\/10.1136\/bmjopen-2016-012832","journal-title":"BMJ Open"},{"key":"3015_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Pedersen L, S\u00f8rensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29:541\u2013549. https:\/\/doi.org\/10.1007\/s10654-014-9930-3","journal-title":"Eur J Epidemiol"},{"key":"3015_CR26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/CLEP.S179083","volume":"11","author":"M Schmidt","year":"2019","unstructured":"Schmidt M, Schmidt SAJ, Adelborg K et al (2019) The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol 11:563\u2013591. https:\/\/doi.org\/10.2147\/CLEP.S179083","journal-title":"Clin Epidemiol"},{"key":"3015_CR27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"3015_CR28","first-page":"141","volume":"5","author":"OO Aalen","year":"1978","unstructured":"Aalen OO, Johansen S (1978) An empirical transition Matrix for Non-homogeneous Markov Chains based on censored observations. Scand J Stat 5:141\u2013150","journal-title":"Scand J Stat"},{"key":"3015_CR29","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","volume":"3","author":"AGG Turpie","year":"2005","unstructured":"Turpie AGG, Fisher WD, Bauer KA et al (2005) BAY 59-7939: an oral, direct factor xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost JTH 3:2479\u20132486. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01602.x","journal-title":"J Thromb Haemost JTH"},{"key":"3015_CR30","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1160\/TH10-02-0142","volume":"104","author":"G Raskob","year":"2010","unstructured":"Raskob G, Cohen AT, Eriksson BI et al (2010) Oral direct factor xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost 104:642\u2013649. https:\/\/doi.org\/10.1160\/TH10-02-0142","journal-title":"Thromb Haemost"},{"key":"3015_CR31","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.2106\/JBJS.L.00882","volume":"95","author":"VK Aggarwal","year":"2013","unstructured":"Aggarwal VK, Tischler EH, Post ZD et al (2013) Patients with Atrial Fibrillation Undergoing Total Joint Arthroplasty Increase Hospital Burden. JBJS 95:1606\u20131611. https:\/\/doi.org\/10.2106\/JBJS.L.00882","journal-title":"JBJS"},{"key":"3015_CR32","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1016\/j.arth.2018.06.022","volume":"33","author":"K Keller","year":"2018","unstructured":"Keller K, Hobohm L, Engelhardt M (2018) Impact of Atrial Fibrillation on postoperative adverse outcomes of Surgical patients with knee endoprosthetic surgery. J Arthroplasty 33:3567\u20133573. https:\/\/doi.org\/10.1016\/j.arth.2018.06.022","journal-title":"J Arthroplasty"},{"key":"3015_CR33","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1177\/1076029618772337","volume":"24","author":"DE Lindquist","year":"2018","unstructured":"Lindquist DE, Stewart DW, Brewster A et al (2018) Comparison of postoperative bleeding in total hip and knee arthroplasty patients receiving Rivaroxaban, Enoxaparin, or aspirin for Thromboprophylaxis. Clin Appl Thromb 24:1315\u20131321. https:\/\/doi.org\/10.1177\/1076029618772337","journal-title":"Clin Appl Thromb"},{"key":"3015_CR34","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.otsr.2020.02.026","volume":"106","author":"J-Y Jenny","year":"2020","unstructured":"Jenny J-Y, Bulaid Y, Boisrenoult P et al (2020) Bleeding and thromboembolism risk of standard antithrombotic prophylaxis after hip or knee replacement within an enhanced recovery program. Orthop Traumatol Surg Res OTSR 106:1533\u20131538. https:\/\/doi.org\/10.1016\/j.otsr.2020.02.026","journal-title":"Orthop Traumatol Surg Res OTSR"},{"key":"3015_CR35","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1016\/j.arth.2020.06.032","volume":"35","author":"AJ Highcock","year":"2020","unstructured":"Highcock AJ, As-Sultany M, Finley R, Donnachie NJ (2020) A prospective cohort comparative study of Rivaroxaban, Dabigatran, and apixaban oral Thromboprophylaxis in 2431 hip and knee arthroplasty patients: primary efficacy outcomes and Safety Profile. J Arthroplasty 35:3093\u20133098. https:\/\/doi.org\/10.1016\/j.arth.2020.06.032","journal-title":"J Arthroplasty"},{"key":"3015_CR36","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s11999-017-5394-6","volume":"475","author":"A Bala","year":"2017","unstructured":"Bala A, Huddleston JII, Goodman SB et al (2017) Venous thromboembolism Prophylaxis after TKA: aspirin, Warfarin, Enoxaparin, or factor xa inhibitors? Clin Orthop Relat Res 475:2205. https:\/\/doi.org\/10.1007\/s11999-017-5394-6","journal-title":"Clin Orthop Relat Res"},{"key":"3015_CR37","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1302\/0301-620X.103B10.BJJ-2021-0023.R1","volume":"103\u2013B","author":"AB Schelde","year":"2021","unstructured":"Schelde AB, Petersen J, Jensen TB et al (2021) Thromboembolic and bleeding complications following primary total knee arthroplasty. Bone Jt J 103\u2013B:1571\u20131577. https:\/\/doi.org\/10.1302\/0301-620X.103B10.BJJ-2021-0023.R1","journal-title":"Bone Jt J"},{"key":"3015_CR38","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.arth.2016.09.021","volume":"32","author":"D Gomez","year":"2017","unstructured":"Gomez D, Razmjou H, Donovan A et al (2017) A phase IV study of thromboembolic and bleeding events following hip and knee arthroplasty using oral factor xa inhibitor. J Arthroplasty 32:958\u2013964. https:\/\/doi.org\/10.1016\/j.arth.2016.09.021","journal-title":"J Arthroplasty"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03015-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-03015-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03015-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T13:07:31Z","timestamp":1729602451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-03015-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3015"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-03015-9","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"assertion":[{"value":"21 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Registry based studies do not require formal ethical approval according to Danish law. The study was reported to the Danish Data Protection Agency through registration at Aarhus University (record number: AU-2016-051-000001, sequential number 880).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of potential conflicts of interest"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}